Table 1.
Clinical characteristics and distribution of amikacin of hospitalized patients
| Parameter | Mean ± SD | Median [range] |
|---|---|---|
| Male/female | 25/10 | |
| Age (years) | 67.5 ± 17.3 | 70.0 [15–95] |
| Weight (kg) | 50.4 ± 10.4 | 49.5 [32.5–78] |
| Lean body weight (kg) | 40.8 ± 8.8 | 42.3 [24.6–58.4] |
| BMI (kg/m2) | 19.6 ± 3.1 | 19.7 [13.4–26.4] |
| Ideal body weight (kg) | 56.8 ± 7.8 | 57.5 [40.1–68.1] |
| Albumin (g/dL) | 2.7 ± 0.6 | 2.6 [1.7–4.3] |
| Serum creatinine (mg/dL) | 1.14 ± 1.23 | 0.61 [0.2–5.6] |
| CCra (mL/min) | 60.3 ± 33.9 | 60.0 [6.1–144] |
| AST (U/L) | 41.3 ± 39.7 | 31 [6–243] |
| ALT (U/L) | 35.2 ± 21.1 | 33 [7–91] |
| BUN (mg/dL) | 24.0 ± 17.7 | 16.4 [5.9–71.6] |
| Total bilirubin (mg/dL) | 0.88 ± 0.81 | 0.55 [0.22–3.47] |
| Duration of amikacin therapy (days) | 13.6 ± 26.5 | 8 [3–162] |
| Amikacin dosage (mg/day) | 513 ± 258 | 400 [200–1000] |
| Amikacin dosage (mg/kg/day) | 10.0 ± 3.9 | 9.6 [3.1–17.7] |
| Infusion time (h) | 0.68 ± 0.38 | 0.5 [0.5–2.0] |
Numerical data are shown as mean ± SD
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, BUN blood urea nitrogen, CCr creatinine clearance, CL total body clearance, SD standard deviation
aCCr estimates calculated according to the Cockcroft–Gault equation